Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Hospital Santa Creu i Sant Pau
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers: male subjects aged between 18 and 45 years
- Body weight: 65-75 Kg
- Not meaningful abnormalities in physical examination and in clinical history
- Without evidence of significant organic or psychiatric illness
- Hemogram, biochemistry and coagulation in normal values established in the reference range of the local hospital laboratory
- Vital signs (blood pressure, heart beat rate and body temperature) and EKG within normal range
- Healthy volunteers who are not participating in another clinical trial or have not done so in the past 2 months
- Not give blood in the last 4 weeks.
- Healthy male volunteers who have not received heparin in the past
- Healthy male volunteers who have accepted to participate in the study and have signed the written informed consent
Exclusion Criteria:
- Previous history of alcoholism, drug dependency, drug abuse or habitual psychoactive drugs consumption
- Important consumption of exciting drinks: alcohol consumption > 30 g/day; coffee, tea, cola > 5 /day
- Allergy, idiosyncrasy or hypersensitivity to medicines
- Healthy volunteers who are receiving another medication in the past 15 days
- Positive serology of hepatitis B, C or HIV
- Cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematologic, psychiatric, neurological and others events
- Mayor Surgery in the last 6 months
- Smoking > 10 cigarettes / day
- Ethanol, cannabis, cocaine, amphetamine, benzodiazepine or opiate in urine
- Healthy volunteers with a familiar history evident hemorrhagic episodes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Ro-14
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Main objective : To evaluate safety and tolerability of increasing single-doses to healthy male volunteers
Time Frame: safety parameters
|
safety parameters
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Secondary objectives : To evaluate pharmacokinetics profiles of each of single-doses.
Time Frame: anti-Xa activity
|
anti-Xa activity
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dr Manuel Barbanoj, Hospital Santa Creu i Sant Pau
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- ROV-RO14-2006-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.